ID: ALA2322194

Max Phase: Preclinical

Molecular Formula: C21H27N5O4S

Molecular Weight: 445.55

Molecule Type: Small molecule

Representations

Canonical SMILES:  NS(=O)(=O)OC[C@@H]1C[C@@H](N2CCc3c(N[C@H]4CCc5ccccc54)ncnc32)C[C@@H]1O

Standard InChI:  InChI=1S/C21H27N5O4S/c22-31(28,29)30-11-14-9-15(10-19(14)27)26-8-7-17-20(23-12-24-21(17)26)25-18-6-5-13-3-1-2-4-16(13)18/h1-4,12,14-15,18-19,27H,5-11H2,(H2,22,28,29)(H,23,24,25)/t14-,15+,18-,19-/m0/s1

Standard InChI Key:  AQGFWBQRVLPCIX-QXGSTGNESA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 445.55

Molecular Weight (Monoisotopic): 445.1784

AlogP: 1.30

#Rotatable Bonds: 6

Polar Surface Area: 130.67

Molecular Species: NEUTRAL

HBA: 8

HBD: 3

#RO5 Violations: 0

HBA (Lipinski): 9

HBD (Lipinski): 4

#RO5 Violations (Lipinski): 0

CX Acidic pKa: 11.40

CX Basic pKa: 6.73

CX LogP: 1.47

CX LogD: 1.39

Aromatic Rings: 2

Heavy Atoms: 31

QED Weighted: 0.61

Np Likeness Score: -0.06

References

1. da Silva SR, Paiva SL, Lukkarila JL, Gunning PT..  (2013)  Exploring a new frontier in cancer treatment: targeting the ubiquitin and ubiquitin-like activating enzymes.,  56  (6): [PMID:23360215] [10.1021/jm301420b]

2.  (2008)  Heteroaryl compounds useful as inhibitors of E1 activating enzymes, 

3. Zhou H, Zhou W, Zhou B, Liu L, Chern TR, Chinnaswamy K, Lu J, Bernard D, Yang CY, Li S, Wang M, Stuckey J, Sun Y, Wang S..  (2018)  High-Affinity Peptidomimetic Inhibitors of the DCN1-UBC12 Protein-Protein Interaction.,  61  (5): [PMID:29438612] [10.1021/acs.jmedchem.7b01455]

Source

Source(2):

• Scientific Literature
• Patent Bioactivity Data